AdiaVita and glutathione for autism in kids and teens
Official title: Greater Atlanta Integrative Pediatrics Autism Spectrum Disorder Research Study
Run by Greater Atlanta Integrative Pediatrics · NCT07622316 · Data updated 2026-11-12
This study tests whether adding AdiaVita (cord-blood stem cells and exosomes) to glutathione helps improve ASD symptoms in children and other participants compared with glutathione alone.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 3 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Greater Atlanta Integrative Pediatrics Academic / other |
| Locations | 2 sites (Roswell, Georgia and 1 other locations) |
| Status | Recruiting |
| Started | June 1, 2026 |
| Main results expected | December 31, 2026 |
| Study ends | June 30, 2027 |
| Registry record updated | June 3, 2026 |
| Trial ID | NCT07622316 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children and adults aged 3 years and older with a confirmed ASD diagnosis who can attend study visits and have parental/guardian consent.
✕Probably not a fit
Participants with uncontrolled medical conditions, immune compromise, ongoing interventional trial participation, or intolerance to study products may not benefit and could be excluded based on safety criteria.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 1 randomized, participant-blinded crossover trial enrolling about 100 individuals aged 3 and older with autism. Participants are assigned to three monthly infusions of AdiaVita plus glutathione or placebo saline with glutathione, followed by a potential crossover to the experimental treatment for eligible controls. The primary outcome is change in Autism Treatment Evaluation Checklist (ATEC) scores, with safety monitored for 12 months. The study is investigational and not FDA-approved for autism, and procedures include bloodwork and regular visits, conducted largely in the Atlanta area. Participants and families should note the cost of the initial treatment schedule and the importance of adherence to study visits and safety follow-up.
Why it matters
Potential benefit: If successful, the treatment could offer a new approach that may reduce ASD-related symptoms and improve quality of life for some participants.
How similar studies have gone: Prior cord blood studies in pediatric ASD have suggested acceptable safety, but this approach remains investigational with limited efficacy data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 3 years and up * Confirmed ASD diagnosis (DSM-5 criteria, supported by ADOS-2 or its equivalent) * Parent/guardian willingness to consider experimental treatments and comply with study requirements * Ability to obtain required bloodwork * Ability to attend all scheduled visits Exclusion Criteria: * Severe allergies to study products * Significant uncontrolled medical conditions * Immunocompromised * Malignancy history * Unstable medication regimen or inconsistent medication adherence (e.g., frequent medication changes or missed doses) within 30 days prior to Baseline, at Investigator discretion * Pregnancy or breastfeeding (if applicable) * Participation in another interventional trial within 30 days
Where it's running
-
Greater Atlanta Integrative Pediatrics
Roswell, Georgia, United States Recruiting -
Greater Atlanta Integrative Pediatrics
Roswell, Georgia, United States Recruiting
Study contacts
- Principal investigator: Maia Gaither, MD — Greater Atlanta Integrative Pediatrics
- Study coordinator: Maia Gaither, MD
- Email: intakes@gaipeds.com
- Phone: 4047513693
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Do AdiaVita stem cells plus glutathione help kids with autism more than glutathione alone?
This 12-month study tests whether adding AdiaVita stem cells and exosomes to glutathione helps children aged 3–12 with autism more than glutathione alone.
-
Online test of BlinkLab Dx1 for autism in kids aged 2–11
This study tests whether the BlinkLab Dx1 smartphone app can help identify autism in children aged 2 to 11 by comparing app-based measurements with prior clinical diagnoses.
-
Comparing center-based and home-based treatment for young children with autism
This study tests whether treatment for young children with autism works better when done at a center or at home, focusing on improving their language and social skills.
-
Museum visits to support social and emotional well‑being in autistic adults
This study tests whether visiting the National Taiwan Museum can help improve social participation and well-being for autistic adults aged 18–50.
-
Two-week intensive brain-focused therapy program for children with neurodevelopmental and chromosomal conditions
This program will try a two-week, individualized multimodal neurorehabilitation approach for children about 4–12 years old with neurodevelopmental or chromosomal conditions to see if it improves attention, motor skills, communication, and daily functioning.
-
Gut barrier and gut microbes in children with autism
This trial will test whether a one-month course of postbiotic supplements can improve gut symptoms and behavior in children with autism aged 3–8.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.